Literature DB >> 22382782

Knocking down nucleolin expression in gliomas inhibits tumor growth and induces cell cycle arrest.

Zhiqiang Xu1, Neel Joshi, Ashima Agarwal, Sonika Dahiya, Patrice Bittner, Erin Smith, Sara Taylor, David Piwnica-Worms, Jason Weber, Jeffrey R Leonard.   

Abstract

Nucleolin is a multifunctional protein whose expression often correlates with increased cellular proliferation. While the expression of nucleolin is often elevated in numerous cancers, its expression in normal human brain and in astrocytomas has not been previously reported. Using paraffin-embedded sections from normal adult autopsy specimens and glioma resection specimens, we demonstrate that nucleolin expression is limited in the normal human brain specifically to mature neurons, ependymal cells, and granular cells of the dentate gyrus. While astrocytes in the normal human brain do not express nucleolin at significant levels, glioblastoma cell lines and primary human astrocytoma cells exhibit considerable nucleolin expression. Reduction of nucleolin expression through siRNA-mediated knockdown in the U87MG glioblastoma cell line caused a dramatic decrease in cell proliferation and induced cell cycle arrest in vitro. Moreover, conditional siRNA knockdown of nucleolin expression in U87MG intracranial xenografts in nude mice caused dramatic reduction in tumor size. Taken together, these results implicate nucleolin in the regulation of human astrocytoma proliferation in vitro and tumorigenicity in vivo and suggest that nucleolin may represent a potential novel therapeutic target for astrocytomas.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22382782     DOI: 10.1007/s11060-012-0827-2

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  34 in total

1.  Nucleolin inhibits Hdm2 by multiple pathways leading to p53 stabilization.

Authors:  A Saxena; C J Rorie; D Dimitrova; Y Daniely; J A Borowiec
Journal:  Oncogene       Date:  2006-06-05       Impact factor: 9.867

2.  Real-time imaging of ligand-induced IKK activation in intact cells and in living mice.

Authors:  Shimon Gross; David Piwnica-Worms
Journal:  Nat Methods       Date:  2005-08       Impact factor: 28.547

3.  Identification of a 110-kDa nonintegrin cell surface laminin-binding protein which recognizes an A chain neurite-promoting peptide.

Authors:  H K Kleinman; B S Weeks; F B Cannon; T M Sweeney; G C Sephel; B Clement; M Zain; M O Olson; M Jucker; B A Burrous
Journal:  Arch Biochem Biophys       Date:  1991-11-01       Impact factor: 4.013

4.  Targeted inhibition of cyclic AMP phosphodiesterase-4 promotes brain tumor regression.

Authors:  Patricia Goldhoff; Nicole M Warrington; David D Limbrick; Andrew Hope; B Mark Woerner; Erin Jackson; Arie Perry; David Piwnica-Worms; Joshua B Rubin
Journal:  Clin Cancer Res       Date:  2008-12-01       Impact factor: 12.531

Review 5.  Molecular dissection of nucleolin's role in growth and cell proliferation: new insights.

Authors:  M Srivastava; H B Pollard
Journal:  FASEB J       Date:  1999-11       Impact factor: 5.191

6.  Overexpression of nucleolin in chronic lymphocytic leukemia cells induces stabilization of bcl2 mRNA.

Authors:  Yoko Otake; Sridharan Soundararajan; Tapas K Sengupta; Ebenezer A Kio; James C Smith; Mauricio Pineda-Roman; Robert K Stuart; Eleanor K Spicer; Daniel J Fernandes
Journal:  Blood       Date:  2007-04-01       Impact factor: 22.113

7.  Multifactorial analysis of predictors of outcome in pediatric intracranial ependymoma.

Authors:  Lee Ridley; Ruman Rahman; Marie-Anne Brundler; David Ellison; James Lowe; Keith Robson; Emma Prebble; Inga Luckett; Richard J Gilbertson; Sheila Parkes; Vikki Rand; Beth Coyle; Richard G Grundy
Journal:  Neuro Oncol       Date:  2008-08-13       Impact factor: 12.300

8.  In vitro characterization of a targeted, dye-loaded nanodevice for intraoperative tumor delineation.

Authors:  Daniel A Orringer; Yong-Eun L Koo; Thomas Chen; Gwangseong Kim; Hoe Jin Hah; Hao Xu; Shouyan Wang; Richard Keep; Martin A Philbert; Raoul Kopelman; Oren Sagher
Journal:  Neurosurgery       Date:  2009-05       Impact factor: 4.654

9.  Nucleolin interacts with telomerase.

Authors:  Shilagardi Khurts; Kenkichi Masutomi; Luvsanjav Delgermaa; Kuniaki Arai; Naoki Oishi; Hideki Mizuno; Naoyuki Hayashi; William C Hahn; Seishi Murakami
Journal:  J Biol Chem       Date:  2004-09-14       Impact factor: 5.157

10.  Nucleolin as cell surface receptor for tumor necrosis factor-alpha inducing protein: a carcinogenic factor of Helicobacter pylori.

Authors:  Tatsuro Watanabe; Hideaki Tsuge; Takahito Imagawa; Daisuke Kise; Kazuya Hirano; Masatoshi Beppu; Atsushi Takahashi; Kensei Yamaguchi; Hirota Fujiki; Masami Suganuma
Journal:  J Cancer Res Clin Oncol       Date:  2010-01-05       Impact factor: 4.553

View more
  22 in total

1.  Nuclear Protein C23 on the Cell Surface Plays an Important Role in Activation of CXCR4 Signaling in Glioblastoma.

Authors:  Congxin Dai; Shunzeng Lv; Ranran Shi; Jing Ding; Xiao Zhong; Huishu Song; Xiaochen Ma; Jianzhen Fan; Bowen Sun; Renzhi Wang; Wenbin Ma
Journal:  Mol Neurobiol       Date:  2014-11-04       Impact factor: 5.590

2.  Human anti-nucleolin recombinant immunoagent for cancer therapy.

Authors:  Dario Palmieri; Timothy Richmond; Claudia Piovan; Tyler Sheetz; Nicola Zanesi; Fulvia Troise; Cindy James; Dorothee Wernicke; Fata Nyei; Timothy J Gordon; Jessica Consiglio; Francesco Salvatore; Vincenzo Coppola; Flavia Pichiorri; Claudia De Lorenzo; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-13       Impact factor: 11.205

3.  The implications and mechanisms of the extra-nuclear nucleolin in the esophageal squamous cell carcinomas.

Authors:  Jiafeng Qi; Huiling Li; Nanbo Liu; Yutong Xing; Gang Zhou; Yao Wu; Yuanhang Liu; Wenxia Chen; Jie Yue; Bater Han; Shirong Kang; Xu Wu
Journal:  Med Oncol       Date:  2015-01-29       Impact factor: 3.064

4.  Cell surface nucleolin facilitates enterovirus 71 binding and infection.

Authors:  Pei-Yi Su; Ya-Fang Wang; Sheng-Wen Huang; Yu-Chih Lo; Ya-Hui Wang; Shang-Rung Wu; Dar-Bin Shieh; Shun-Hua Chen; Jen-Ren Wang; Ming-Der Lai; Chuan-Fa Chang
Journal:  J Virol       Date:  2015-02-11       Impact factor: 5.103

5.  Nucleolin overexpression is associated with an unfavorable outcome for ependymoma: a multifactorial analysis of 176 patients.

Authors:  Chunjui Chen; Lingchao Chen; Yu Yao; Zhiyong Qin; Hong Chen
Journal:  J Neurooncol       Date:  2015-11-28       Impact factor: 4.130

6.  Involvement of nuclear protein C23 in activation of EGFR signaling in cervical cancer.

Authors:  Junyuan Yan; Yanling Zhang; Cuili Ren; Wenshuang Shi; Lijun Chen
Journal:  Tumour Biol       Date:  2015-08-10

7.  Cell surface protein C23 affects EGF-EGFR induced activation of ERK and PI3K-AKT pathways.

Authors:  Shunzeng Lv; Congxin Dai; Yuting Liu; Bowen Sun; Ranran Shi; Mingzhi Han; Ruixiang Bian; Renzhi Wang
Journal:  J Mol Neurosci       Date:  2015-02       Impact factor: 3.444

8.  Cell surface nucleolin is crucial in the activation of the CXCL12/CXCR4 signaling pathway.

Authors:  Xiangshan Yang; Zhongfa Xu; Daotang Li; Shaomei Cheng; Kaixi Fan; Chengjun Li; Aiping Li; Jing Zhang; Man Feng
Journal:  Tumour Biol       Date:  2013-08-06

9.  Tissue and cellular characterisation of nucleolin in a murine model of corneal angiogenesis.

Authors:  Joaquín Quiroz-Mercado; Norma Ramírez-Velázquez; Graciela Partido; Edgar Zenteno; Raúl Chávez; Concepción Agundis-Mata; Maria Carmen Jiménez-Martínez; Yonathan Garfias
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-06-16       Impact factor: 3.117

10.  A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma.

Authors:  Jonathan E Rosenberg; Richard M Bambury; Eliezer M Van Allen; Harry A Drabkin; Primo N Lara; Andrea L Harzstark; Nikhil Wagle; Robert A Figlin; Gregory W Smith; Levi A Garraway; Toni Choueiri; Fredrik Erlandsson; Damian A Laber
Journal:  Invest New Drugs       Date:  2013-11-16       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.